Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria
about
The relative merits of therapies being developed to tackle inappropriate ('self'-directed) complement activationViral-derived complement inhibitors: current status and potential role in immunomodulation.Interim analysis of post-marketing surveillance of eculizumab for paroxysmal nocturnal hemoglobinuria in Japan.Atypical presentation of paroxysmal nocturnal hemoglobinuria treated by eculizumab: A case report.Recurrent cerebral ischaemic events in the setting of paroxysmal nocturnal haemoglobinuria.
P2860
Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria
@ast
Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria
@en
Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria
@nl
type
label
Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria
@ast
Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria
@en
Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria
@nl
prefLabel
Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria
@ast
Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria
@en
Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria
@nl
P2860
P50
P1476
Eculizumab for treating patients with paroxysmal nocturnal hemoglobinuria
@en
P2093
Vidhu Anand
P2860
P304
P356
10.1002/14651858.CD010340.PUB2
P407
P577
2014-10-30T00:00:00Z